I'm looking forward to presenting at the Stifel 2023 CNS Days today. For more details about the event, visit: bit.ly/3lNBXs9 Gate Neurosciences

As part of our commitment to #mentalhealth innovation, we recently expanded our research facilities in Evanston! This renewed effort includes advancing translational EEG biomarkers supporting our '-stinel' programs that enhance synaptic function. businesswire.com/news/home/2023…

Looking forward to ASCP Annual Meeting American Society of Clinical Pschopharm (ASCP) in Miami next week, where we will be presenting new data on precision medicine approaches ad translational tools #neurosciences #mentalhealth Gate Neurosciences businesswire.com/news/home/2023…

In more than a third of patients with major depression, treatment with antidepressant drugs fails to control symptoms. Read the full ELEKT-D trial Research Summary: nej.md/3ODZMPc

.Eli Lilly and Company's acquisition of @VersanisBio is a quintessential example of how a dormant, unappreciated, or non-strategic asset stalled in a pharma pipeline (in this instance from Novartis Science) can be given new life by a dedicated management and investor team (more...)

In this article, Gate Neurosciences details their role on taking on depression with event-driven #pharmacology. They also discuss he challenges & promise of NMDA receptor #modulation, the role of EEG #biomarkers in #DrugDevelopment & much more: drugdiscoverytrends.com/gate-neuroscie…

Amazing 🤯

🌍 Today we celebrate mental health around the world—because every mind matters. 💚 Let's foster understanding, empathy, and support for one another. 🤝 #WorldMentalHealthDay #MentalHealthMatters 🌍

#WorldMentalHealthDay

Great to see coverage in WIRED on the link between #neuroplasticity and #depression. Current antidepressants take weeks to work. We are developing a new class of drugs targeting the #glutamate system to rapidly enhance neuroplasticity within hours to days. #mentalhealth

Looking forward to presenting at CNS Summit next week in Boston! #cnssummit2023 #neuroscience #mentalhealth #neuroplasticity #drugdevelopment #biopharma #innovation #pharma cvent.me/ArY8OB?refid=s…

Nice The Atlantic piece on how psychedelics hallucinogenic effects may not drive #mentalhealth outcomes - its the impact on neuroplasticity. Our novel drug candidates can safely enhance plasticity & strengthen neural connections to treat disease from #MDD to #alzheimers & #autism

Our lead program, zelquistinel, was included in a recent review paper from UTHealth Houston on GABA-glutamate targeted drugs: mdpi.com/1424-8247/16/1… "Future treatment models need to consider nuances of glutamate signaling with regard to timing & duration of action"...we agree!

New white paper out today! From our team at Gate Neurosciences describing our insights into harnessing the potential of new treatments targeting synaptic structure and function. ddw-online.com/reshaping-neur…

Dr. Anantha Shekhar spoke about the development of GATE-251, a positive allosteric modulator of the NMDA receptor to treat MDD in subjects with insomnia and anxiety in a Phase 2a study that demonstrated rapid efficacy which warrants further investigation.